Updated from 4:34 p.m. ESTWhile Gilead Sciences ( GILD - Get Report) saw its fourth-quarter revenue jump, the company reported mixed sales results for some of its major drugs, sending its shares lower in after-hours trading. According to Gilead, fourth-quarter revenue rose 65% from a year ago, and product sales climbed for the ninth straight quarter thanks to its HIV drug Truvada and hepatitis B treatment Hepsera. Sales of Truvada, the company's biggest HIV drug, rose 18% from the third quarter to $191.1 million, but analysts were disappointed. Forecasters expected Truvada sales to reach $197 million. The drug, which launched in the U.S. in the third quarter of 2004 and in certain European countries in 2005, accounted for 50% of Gilead's total HIV product sales for the fourth quarter. As patients switched over to Truvada from Viread, sales of the older HIV drug fell 8% from the 2004 fourth quarter to $182.4 million. Sales of another HIV drug, Emtriva, slid 15% from a year ago to $11.2 million, but the decline wasn't as bad as the expected drop to $9.3 million. Sales of AmBisome, a treatment for severe fungal infections, and Hepsera were stronger than anticipated. AmBisome brought in $55.6 million in sales for the fourth quarter, up 1%, while revenue from Hepsera totaled $51.2 million, a 43% increase. Overall, product sales totaled $493.4 million. The company's HIV product line had sales of $384.8 million in the fourth quarter, a 47% increase from the same period in 2004, but slightly lower than the consensus projection of $389.8 million. All told, the Foster City, Calif., biopharmaceutical company posted revenue of $609.3 million for the quarter, up from $369.6 million in the same period a year ago. Gilead earned $281.6 million, or 59 cents a share, for the last three months of the fiscal year, more than double the $110.2 million and 24 cents a share last year. Excluding a tax benefit realized from the repatriation of foreign earnings, Gilead would have earned $256.5 million, or 54 cents a share, in the most recent quarter, the company said Monday.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Beyond Meat Slides After Andrew Left's Citron Slams Stock in Tweet
Newly public meat-alternative company sees shares lower on short-seller's critique.
Baidu, Alibaba and Tencent All Reported This Week: A Chinese Tech Scorecard
China's tech giants gave a look into how they're faring amid trade worries and other macro factors.
Stock Exchanges in Need of Reform. Is the Long-Term Stock Exchange the Answer?
Tech companies could find a friendly home in the Long-Term Stock Exchange, but whether everyday investors will embrace remains an open question.
Kohl's and 2 Other Retail Earnings That Every Investor Should Watch Next Week
Feeling overwhelmed as the markets gear up for retail earnings palooza? Action Alerts PLUS senior analyst Jeff Marks is watching three key retail earnings.